Insider Selling: uniQure (NASDAQ:QURE) CFO Sells 10,438 Shares of Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 10,438 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the sale, the chief financial officer now owns 217,730 shares of the company’s stock, valued at approximately $2,240,441.70. This represents a 4.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12.
• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The stock was sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Stock Up 6.7 %

Shares of NASDAQ QURE opened at $12.09 on Thursday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The firm has a 50-day moving average price of $14.69 and a 200 day moving average price of $9.91. The stock has a market capitalization of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Leerink Partners increased their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday, February 5th. Stifel Nicolaus raised their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Finally, Wells Fargo & Company reduced their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $38.89.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares during the period. Tudor Investment Corp ET AL lifted its stake in shares of uniQure by 5.9% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after purchasing an additional 1,371 shares during the period. Wells Fargo & Company MN increased its holdings in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares in the last quarter. Northern Trust Corp increased its holdings in uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after acquiring an additional 3,996 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.